Quest Diagnostics

Quest Diagnostics stock climbed to a new all-time high of $246.06 and is up about 43% year-to-date. In the second quarter the company beat adjusted EPS of $3.12 (consensus $2.82) and revenue of $3.04 billion and raised its full-year outlook. Truist Securities raised its price target to $250 while maintaining a "hold" rating. An InvestingPro analysis classifies the stock as overvalued but rates the financial situation as "VERY GOOD"; Quest Diagnostics also raised its dividend for the 15th consecutive year. » Plus sur de.investing.com

Quest Diagnostics is adding Roche’s FDA‑cleared Elecsys pTau217 blood test to its AD‑Detect portfolio and plans to offer it to physicians and study partners in Q4 2026. At the same time, Quest will launch its own multi‑biomarker test (Aβ42/40, p‑tau217 and ApoE) at the end of August; using mass spectrometry it generates a score to predict Alzheimer’s pathology and showed only a 10% rate of indeterminate results in studies. The tests will be available through about 2,000 Quest patient service centers as well as physician offices and mobile services, and Quest plans to integrate the pTau217 test into future AD‑Detect lines starting in 2027. » Plus sur de.investing.com

Quest Diagnostics stock reached a new all-time high of $240.15 and is trading near its 52-week high, with a year-to-date gain of about 38% and a market value of $26.35 billion. In Q2 the company beat expectations with adjusted EPS of $3.12 (consensus $2.82) and revenue of $3.04 billion, after which it raised its full-year outlook. InvestingPro currently classifies the stock as overvalued, while Truist Securities raised the price target to $250 and affirmed a "hold" rating. » Plus sur de.investing.com